Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page ) \1 ?* ^1 b4 t
6 _/ ^/ d1 n# e& P8 [
% g; R6 ~; A6 U4 X- y% k+ ^Sub-category:
- Q- e% e( Q/ Y' |3 x+ nMolecular Targets & y9 A7 g& z' M2 v1 \& u
. o2 I* B8 u0 V0 H+ e, ~, a1 f+ t( _) Q9 T- S7 g
Category:0 h/ ]! {+ | T6 ?/ T2 k
Tumor Biology & o3 e/ t- e7 a
- ?" U0 y8 K; ]6 v* v; |2 |
. j& O6 [ g+ s! i! r
Meeting:
& d1 U0 i9 P3 f: L2011 ASCO Annual Meeting
9 K/ C" a$ [7 m- F4 c( H& v4 ?% K1 S" B$ i6 a% }4 m
o8 C8 J9 o. r$ l. T7 C1 XSession Type and Session Title:/ j0 H1 |# C {8 H5 H# X$ `
Poster Discussion Session, Tumor Biology
. n; y1 o5 E) x( y# [
, s% t' c8 v$ ]6 v* Z+ b3 K; t4 h, D H1 r1 e
Abstract No:
: l* ~/ z; j$ e" S& k10517
* U3 c; g ]) X
$ p- |- J k8 H) M |* l7 m8 e" h: N* @( S! X u K# ?/ L
Citation:9 L! `0 B. `# Q7 Z. i& |5 s
J Clin Oncol 29: 2011 (suppl; abstr 10517) 1 Y4 j' r: p& V% N& Z% u! U: n- g
6 `# e. L3 H7 W" C# I1 f4 E1 M
# H1 @3 O3 I; x. yAuthor(s):
% J: e$ N3 A, P( g: I# N' U2 kJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 4 k; u- V1 l9 M& @( I) e
4 o j$ K4 R; a- ?* }& q8 r3 o" L! Q: F6 x, _3 Z
! ~4 |% u3 y6 K' G9 N
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.2 N# u- E$ [3 f/ T
. J; s+ T# F. W9 ^1 I
Abstract Disclosures; | N/ ] k$ g" h/ ~
$ @, D3 B/ U5 i* o
Abstract:
$ q3 A/ ~' |3 |' r' O% G
# `9 M% ?# |' v$ B/ M! f: `; E
6 ?+ c* L9 Y) ]: bBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation./ h1 V x. y) u1 E/ j
; t4 f8 P. k7 t8 e3 {3 f
' g( n+ u3 N* e8 ?! c
|